Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery

Inclusion Criteria

• Patients must have histologically or cytologically confirmed squamous cell carcinoma or adenosquamous carcinoma of the cervix, or adenocarcinoma of the cervix
• Patients must have unresectable, locally advanced or metastatic disease, incurable by standard therapies
• Patients must have tumor tissue from their primary tumor available
• Presence of clinically and/or radiologically documented disease
• Chest x-ray >= 20 mm
• Computed tomography (CT) scan (with slice thickness of = = 10 mm: longest diameter
• Physical exam (using calipers) >= 10 mm
• Lymph nodes by CT scan >= 15 mm: measured in short axis
• All radiology studies must be performed within 21 days prior to registration (within 28 days if negative)
• Patients must have a life expectancy of at least 12 weeks
• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
• Patients may have had up to one prior chemotherapy regimen; a minimum of 28 days (4 weeks) must have elapsed between the end of chemotherapy and study registration; Note: Radiotherapy with concurrent radiosensitizing cisplatin at the time of initial diagnosis and treatment is permitted, and is not considered systemic chemotherapy
• Patients may have had prior radiation therapy; a minimum of 28 days must have elapsed between the end of radiotherapy and registration onto the study; (exceptions may be made however, for low dose, palliative radiotherapy); patients must have recovered from any acute toxic effects from radiation prior to registration
• Previous major surgery is permitted provided that it has been at least 28 days prior to patient registration and that wound healing has occurred
• Granulocytes (AGC) >= 1.5 x 10^9/L
• Platelets >= 100 x 10^9/L
• Serum creatinine = = 5 years
• Patients must not have had prior treatment with an mTOR inhibitor
• Pregnant or lactating women; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with temsirolimus; if the patient is of childbearing potential, a urine beta (β)-human chorionic gonadotropin (HCG) must be proved negative within 7 days prior to registration; women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
• Patients with known brain metastases (a brain CT is not necessary to rule out brain metastases, unless there is clinical suspicion of CNS involvement); patients with known brain metastases will be excluded from this trial
• Patients with serious cardiovascular illness such as myocardial infarction within 6 months prior to entry, congestive heart failure (even if medically controlled), unstable angina, active cardiomyopathy, unstable ventricular arrhythmia or uncontrolled hypertension
• Patients who require use of therapeutic anticoagulation are ELIGIBLE but must have their prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) monitored closely during therapy
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to temsirolimus
• Patients receiving concurrent treatment with other anti-cancer therapy or other investigational agents
• Serious illness or medical condition which would not permit the patient to be managed according to the protocol including, but not limited to:
• History of significant neurologic or psychiatric disorder which would impair the ability to obtain consent or limit compliance with study requirements
• Active uncontrolled infection or non-healing wounds
• Active peptic ulcer disease
• Active bleeding or any other medical conditions that might be aggravated by treatment
• Symptomatic congestive heart failure, unstable angina, cardiac arrhythmia
• Fistula or history o